Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK 2189242A
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
GSK 2189242A is an investigational protein-based vaccine developed by GSK for the prevention of infections caused by *Streptococcus pneumoniae*. Unlike traditional pneumococcal conjugate vaccines (PCVs) which target the polysaccharide capsule of specific serotypes, this vaccine utilizes novel, conserved, recombinant surface proteins as antigens. This approach aims to provide broader, serotype-independent protection by targeting protein antigens that are present across multiple pneumococcal strains. The vaccine has been evaluated in Phase 2 clinical trials, particularly in infant and pediatric populations, to assess its safety, immunogenicity, and impact on nasopharyngeal carriage when co-administered with routine Expanded Programme on Immunization (EPI) vaccines.
- Other names
- GSK pneumococcal protein vaccine
02
Targets
CPS (Streptococcus pneumoniae capsular polysaccharide)PhtD (Pneumococcal histidine triad protein D)Ply (Pneumolysin)
Beyond the preview
Go deeper on GSK 2189242A.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK 2189242A.